4.7 Article

The heritability and genetics of frontotemporal lobar degeneration

Journal

NEUROLOGY
Volume 73, Issue 18, Pages 1451-1456

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181bf997a

Keywords

-

Funding

  1. Department of Health's NIHR Biomedical Research Centres
  2. Wellcome Trust
  3. Medical Research Council Prion Unit
  4. Alzheimer's Research Trust
  5. UCL Hospitals Clinical Research and Development Committee
  6. Elan Corporation
  7. Wyeth
  8. Lundbeck Inc.
  9. Sanofi-Aventis
  10. IXICO Ltd.
  11. Pfizer Inc.
  12. Neurochem Inc.
  13. MRC [G0801306, G0601846]
  14. NIH [U01 AG024904 (Co-I)]
  15. Alzheimer Research Trust [ART/RF/2007/1]
  16. Canadian Institutes of Health Research
  17. Pacific Alzheimer Research Foundation
  18. Michael Smith Foundation for Health Research
  19. The Sarah Matheson Trust
  20. Action Medical Research
  21. BrainNet Europe
  22. Myositis Support Group
  23. Orion Pharma
  24. European Commission
  25. BrainNet Europe II
  26. Network of Excellence
  27. Sarah Matheson Trust
  28. Parkinson's Disease Society, UK
  29. Department of Health
  30. MRC [G0501560, G0601846, G0401247, G0701075, G0801306, MC_U123160651, MC_U123182015] Funding Source: UKRI
  31. Alzheimers Research UK [ART-PhD2007-2] Funding Source: researchfish
  32. Medical Research Council [G0701075, G0601846, MC_U123160651, G0501560, G0401247, G0801306, MC_U123182015] Funding Source: researchfish
  33. National Institute for Health Research [NF-SI-0508-10123] Funding Source: researchfish

Ask authors/readers for more resources

Background: Frontotemporal lobar degeneration (FTLD) is a genetically and pathologically heterogeneous neurodegenerative disorder. Methods: We collected blood samples from a cohort of 225 patients with a diagnosis within the FTLD spectrum and examined the heritability of FTLD by giving each patient a family history score, from 1 (a clear autosomal dominant history of FTLD) through to 4 (no family history of dementia). We also looked for mutations in each of the 5 disease-causing genes (MAPT, GRN, VCP, CHMP2B, and TARDP) and the FUS gene, known to cause motor neuron disease. Results: A total of 41.8% of patients had some family history (score of 1, 2, 3, or 3.5), although only 10.2% had a clear autosomal dominant history (score of 1). Heritability varied across the different clinical subtypes of FTLD with the behavioral variant being the most heritable and frontotemporal dementia-motor neuron disease and the language syndromes (particularly semantic dementia) the least heritable. Mutations were found in MAPT (8.9% of the cohort) and GRN (8.4%) but not in any of the other genes. Of the remaining patients without mutations but with a strong family history, 7 had pathologic confirmation, falling into 2 groups: type 3 FTLD-TDP without GRN mutations (6) and FTLD-UPS (1). Conclusion: These findings show that frontotemporal lobar degeneration (FTLD) is a highly heritable disorder but heritability varies between the different syndromes. Furthermore, while MAPT and GRN mutations account for a substantial proportion of familial cases, there are other genes yet to be discovered, particularly in patients with type 3 FTLD-TDP without a GRN mutation. Neurology (R) 2009; 73:1451-1456

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available